Liquid Biopsies in Ewing Sarcoma

Krumbholz M, Metzler M (2021)

Publication Type: Book chapter / Article in edited volumes

Publication year: 2021

Journal

Methods in Molecular Biology Humana Press

Publisher: Humana Press Inc.

Edited Volumes: Ewing Sarcoma

Series: Methods in Molecular Biology

City/Town: New York

Book Volume: 2226

Pages Range: 39-45

DOI: 10.1007/978-1-0716-1020-6_4

Abstract

Liquid biopsies enable noninvasive therapy monitoring in patients with solid tumors. Specific serum markers such as proteins, hormones, or enzymes released from tumor cells or in response to tumor growth can be used for quantification of the tumor burden. However, only a fraction of pediatric tumors has none of these serum markers, but tumor-specific genetic alterations represent reliable alternatives. Here we describe a method for using genomic fusion sequences as liquid biopsy markers in Ewing sarcoma patients.

Authors with CRIS profile

Manuela Krumbholz Department of Paediatrics and Adolescent Medicine Markus Metzler Professur für Kinder- und Jugendmedizin mit dem Schwerpunkt Pädiatrische Onkologie und Hämatologie

How to cite

APA:

Krumbholz, M., & Metzler, M. (2021). Liquid Biopsies in Ewing Sarcoma. In Florencia Cidre-Aranaz, Thomas G. P. Grünewald (Eds.), Ewing Sarcoma. (pp. 39-45). New York: Humana Press Inc..

MLA:

Krumbholz, Manuela, and Markus Metzler. "Liquid Biopsies in Ewing Sarcoma." Ewing Sarcoma. Ed. Florencia Cidre-Aranaz, Thomas G. P. Grünewald, New York: Humana Press Inc., 2021. 39-45.

BibTeX: Download